Aduro BioTech (ADRO) Earning Somewhat Favorable News Coverage, Study Shows
Press coverage about Aduro BioTech (NASDAQ:ADRO) has trended somewhat positive this week, Accern reports. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aduro BioTech earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.9141730043269 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Aduro BioTech (ADRO) Rating Increased to Sell at ValuEngine (americanbankingnews.com)
- Aduro Biotech to Present at the 28th Annual Oppenheimer Healthcare Conference (finance.yahoo.com)
- Healthcare stock Buyers and Sellers Recap -Aduro BioTech, Inc. (ADRO) – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Aduro BioTech, Inc. (ADRO) receives consensus rating of 1.80 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Monthly Up Look: Aduro BioTech, Inc. (ADRO) stock moves 38.89% – The Stocks News (press release) (thestocksnews.com)
Several research analysts recently issued reports on the company. ValuEngine upgraded Aduro BioTech from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Oppenheimer cut their price objective on Aduro BioTech from $15.00 to $13.00 and set an “outperform” rating for the company in a research report on Wednesday, December 13th. HC Wainwright cut their price objective on Aduro BioTech from $18.00 to $9.50 and set a “buy” rating for the company in a research report on Wednesday, December 13th. BidaskClub downgraded Aduro BioTech from a “hold” rating to a “sell” rating in a report on Saturday, December 9th. Finally, Canaccord Genuity set a $30.00 price target on Aduro BioTech and gave the company a “buy” rating in a report on Thursday, December 14th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $14.50.
In related news, insider Elsas Andrea Van sold 6,874 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $6.48, for a total transaction of $44,543.52. Following the completion of the sale, the insider now directly owns 216,669 shares of the company’s stock, valued at approximately $1,404,015.12. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Gregory W. Schafer sold 20,000 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $7.61, for a total transaction of $152,200.00. Following the sale, the chief operating officer now directly owns 190,745 shares of the company’s stock, valued at $1,451,569.45. The disclosure for this sale can be found here. Insiders have sold a total of 109,758 shares of company stock valued at $894,724 over the last three months. Corporate insiders own 6.60% of the company’s stock.
About Aduro BioTech
Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.